Clinical Trials
Last Updated: 09/07/2010
Untreated
- Indolent Lymphoma
- Intermediate/High Grade Lymphoma
- Hodgkin's Lymphoma
- Mantle Cell Lymphoma
- Peripheral T-Cell Lymphoma
- Multiple Myeloma
Prior Treated
- Indolent Lymphoma
- Intermediate Grade Lymphoma
- Hodgkin Lymphoma
- Mantle Cell Lymphoma
- Peripheral T-Cell Lymphoma
- Multiple Myeloma
- Phase I Agents
Supportive Care
Previous Post-Allo Transplant
Untreated
Indolent Lymphoma
- Lenalidomide, Rituximab (2008-0042)
- Bendamustine, Mitoxantrone, Rituximab (2008-0204)
- Bendamustine, Ofatumumab (2009-0980)
Intermediate/High Grade Lymphoma
Hodgkin's Lymphoma
- ABVD (2007-0144)
- ABVD, Rituximab, XRT (2009-0292)
- ABVD, Brentuximab Vedotin (2009-0801)
- Interim PET response adapted therapy (SWOG SO816)
Mantle Cell Lymphoma
- Bortezomib + R-HyperCVAD alternating with Bortezomib+ R-High dose Methotrexate/Cytarabine (2006-0697)
Peripheral T-Cell Lymphoma
- CHOP, Vorinostat (2008-0484)
Multiple Myeloma/Waldenstrom’s
- Bortezomib, CNTO328, Melphalan, Prednisone (2009-0113)
- Bortezomib, Lenalidomide, Dexamethasone, Vorinostat (2008-0794)
- Bortezomib, Lenalidomide, Dexamethasone (SWOG SO0777)
- Siltuximab (2010-0623)
Prior Treatment
Indolent Lymphoma
- Milatuzumab (2008-0075)
- SB1518 (2008-0105)
- CT-011, Rituximab (2009-0163)
- GA101, Rituximab (2009-0354)
- MK-2206 (2010-0261)
- CMC-544 (2009-0211)
- Bendamustine, GA101 (2010-0197)
- PCI-32765 (2008-0494)
- MLN8237 (2008-0278)
- Panobinostat, Everloimus (2008-0805)
- HCD 122 (2008-0062)
- MLN4924 (2008-0135)
- CNTO 328 (2009-0608)
- MEDI-551 (2010-0181)
- MGCD0103 (2006-0417)
- SB1518 (2010-0492)
Intermediate Grade Lymphoma
- CC-5013 + Rituxan (2005-0461)
- SB1518 (2008-0105)
- MLN 8237 (2008-0278)
- Milatuzumab (2008-0075)
- Ofatumumab, ICE/DHAP (2008-0841)
- Inotuzumab Ozogamicin, RCVP/RGDP (2010-0114)
- Inotuzumab Ozogamicin, Rituximab (2009-0161)
- Revlimid (2010-0272)
- MK-2206 (2010-0261)
- PCI-32765 (2008-0494)
- MLN4924 (2008-0135)
- Panobinostat, Everolimus (2008-0805)
Hodgkin's Lymphoma
- SB1518 (2008-0105)
- HCD 122 (2008-0062)
- Bortezomib, ICE (2008-0604)
- Panobinostat, ICE (2010-0065)
- Brentuximab vedotin (2010-0453)
- Entinostat (2008-0769)
- MK-2206 (2010-0261)
- Panobinostat, Everolimus (2008-0805)
- RAD001 (2010-0228)
- SB1518 (2010-0492)
- AFM13 (2010-0399)
- SGN-35 (2009-0130)
- MLN4924 (2008-0135)
Mantle Cell Lymphoma
- SB1518 (2008-0105)
- MLN8237 (2008-0278)
- Bortezomib, Cyclosphosphamide, Rituximab (2009-0057)
- RAD001 (2008-0436)
- Panobinostat, Everolimus (2008-0805)
- MK-2206 (2010-0261)
- PCI-32765 (2008-0494)
- MLN4924 (2008-0135)
- MEDI-551 (2010-0181)
- SB1518 (2010-0492)
Peripheral T-cell Lymphoma
Multiple Myeloma/Waldenstrom's
- Carfilzomib, Bortezomib, Dexamethasone (2010-0416)
- Lenalidomide, Dexamethasone, Panobinostat (2010-0323)
- Lenalidomide, Dexamethasone, Panobinostat (2010-0398)
- ARRY-520 (2008-0500)
- Dexamethesone, Lenalidomide, Thalidomide (2009-0179)
- MLN9708 (2009-0355)
- MLN4924 (2008-0135)
- Bortezomib, KW2478 (2009-0902)
- hLL1-DOX (2010-0295)
Phase I Agents
- Milatuzumab (2008-0075)
- SB1518 (2008-0105)
- MLN8237 (2008-0278)
- HCD 122 (2008-0062)
- MK-2206 (2010-0261)
- PCI-32765 (2008-0494)
- MLN4924 (2008-0135)
- AFM13 (2010-0399)
- Panobinostat, Everolimus (2008-0805)
Supportive Care
- Acupuncture (2006-0679)
- Minocycline (2006-0022)
WaldenstrÖm's Macroglobulinemia
- Bortezomib, Rituxan (2007-0716)
- RAD001 (2009-0755)
- Pomalidomide (2009-0972)
- Asymptomatic Waldenstrom (2009-0466)